Sulfato de magnesio y aminofilina en el tratamiento de niños, niñas y adolescentes hospitalizados. Perfil de uso y respuesta terapéutica

Introducción: Sulfato de magnesio (MgSO4) y aminofilina son broncodilatadores intravenosos utilizados en el tratamiento de niños con broncoobstrucción (BO). La evidencia disponible para recomendar su uso es escasa. Objetivo: Caracterizar el perfil de uso y la respuesta terapéutica al MgSO4 y aminofilina en el tratamiento de la BO en niños hospitalizados en un centro de referencia de Uruguay. Materiales y métodos: Estudio descriptivo de corte transversal mediante revisión de historias y entrevistas. Se incluyeron a todos los menores de 15 años que utilizaron estos fármacos. Se evaluó la respuesta terapéutica a la administración de ambos fármacos en forma exclusiva y concomitante y la presencia de efectos adversos. Resultados: Se incluyeron 102 niños, mediana de edad 4 años, ≤5 años 62%. Los principales diagnósticos fueron: crisis asmática 56% y neumonía viral 31%. Recibieron ambos fármacos 48%, únicamente aminofilina 28% y exclusiva de MgSO4 24%. Se observó buena respuesta terapéutica a la administración: exclusiva de MgSO4 67%, consecutiva de MgSO4 y aminofilina 45% y exclusiva de aminofilina en 34%. En 38,2% se registró al menos un efecto adverso, 64% eran menores de 5 años, riesgo aumentado en 1,5 veces. Conclusiones: Se registraron variadas indicaciones, la mayoría en niños asmáticos y en un porcentaje menor indicaciones fuera de prospecto. Menos de la mitad presentaron buena respuesta luego de la administración de MgSO4 y/o aminofilina. En un porcentaje no despreciable se registraron efectos adversos, predominaron en menores de 5 años. Son necesarios nuevos estudios para continuar caracterizando el perfil de uso y seguridad de estos fármacos.

Introduction: Magnesium sulfate (MgSO4) and aminophylline are intravenous bronchodilators used in the treatment of children with bronchoobstruction (BO). The evidence available to recommend their use is scarce. Objective: To characterize the use profile and therapeutic response to MgSO4 and aminophylline in the treatment of BO in children hospitalized in a reference center in Uruguay. Materials and methods: This was a descriptive cross-sectional study through review of clinical histories and interviews. All children under 15 years of age who used these drugs were included. The therapeutic response to the administration of both drugs exclusively and concomitantly and the presence of adverse effects were evaluated. Results: 102 children were included, median age was 4 years, 62% were ≤5 years. The main diagnoses were: asthmatic crisis, 56% and viral pneumonia, 31%. 48% received both drugs, 28% only aminophylline and 24% exclusively MgSO4. Good therapeutic response was observed to the administration: MgSO4 exclusively, 67%, MgSO4 followed by aminophylline, 45% and aminophylline exclusively in 34%. At least one adverse effect was recorded in 38.2%, of these, 64% were under 5 years of age, risk increased by 1.5 times. Conclusions: Various indications were recorded, the majority in asthmatic children and a smaller percentage off-label indications. Less than half had a good response after the administration of MgSO4 and/or aminophylline. Adverse effects were recorded in a non-negligible percentage, predominating in children under 5 years of age. New studies are necessary to continue characterizing the use and safety profile of these drugs.

Uterotonics, magnesium sulphate and antibiotics during childbirth and peripartum: Important obstetric drugs for the anaesthesiologist.

The main causes of maternal mortality are comorbidities, hypertensive pregnancy syndrome, obstetric haemorrhage, and maternal sepsis. For this reason, uterotonics, magnesium sulphate, and antibiotics are essential tools in the management of obstetric patients during labour and in the peripartum period. These drugs are widely used by anaesthesiologists in all departments, and play a crucial role in treatment and patient safety. For the purpose of this narrative review, we performed a detailed search of medical databases and selected studies describing the use of these drugs in patients during pregnancy, delivery and the pospartum period. Uterotonics, above all oxytocin, play an important role in the prevention and treatment of pospartum haemorrhage, and various studies have shown that in obstetric procedures, such as scheduled and emergency caesarean section, they are effective at lower doses than those hitherto accepted. We also discuss the use of carbetocin as an effective alternative that has a therapeutic advantage in certain clinical circumstances. Magnesium sulphate is the gold standard in the prevention and treatment of eclampsia, and also plays a neuroprotective role in preterm infants. We describe the precautions to be taken during magnesium administration. Finally, we discuss the importance of understanding microbiology and the pharmacology of antibiotics in the management of obstetric infection and endometritis, and draw attention to the latest trends in antibiotic regimens in labour and caesarean section.

Descripción de los factores contribuyentes a las muertes secundarias a trastornos hipertensivos asociados al embarazo en Antioquia, Colombia (2012-2020) / Description of the contributing factors to deaths secondary to hypertensive disorders associated with pregnancy in Antioquia, Colombia (2012-2020)

Resumen OBJETIVO: Describir las características de la población afectada y los retrasos que contribuyeron a la mortalidad materna, secundaria a los trastornos hipertensivos del embarazo. MATERIALES Y MÉTODOS: Estudio descriptivo y retrospectivo efectuado con base en la vigilancia epidemiológica de casos centinela de muertes maternas tempranas de mujeres residentes en Antioquia, Colombia, durante el embarazo, el parto y los 42 días siguientes a éste ocurridas en el periodo 2012-2020. Se creó una base de datos en Microsoft Access 2007 (Microsoft, Redmond, WA, USA) y los datos se analizaron en Microsoft Excel y SPSS versión 22. RESULTADOS: Se registraron 266 muertes maternas, de las que 38 fueron secundarias a trastornos hipertensivos del embarazo. La eclampsia fue causa de 15 fallecimientos; 12 por síndrome HELLP, 9 por hemorragia intracerebral y 2 por desprendimiento prematuro de placenta y coagulación intravascular diseminada. En 13 de los 38 casos no hubo una pauta adecuada del sulfato de magnesio, 19 no recibieron tratamiento antihipertensivo, que estaba indicado y 17 no tuvieron un control antihipertensivo adecuado. CONCLUSIÓN: La atención prenatal es una oportunidad decisiva para la detección, prevención y estratificación del riesgo. Todos los centros de atención obstétrica deben estar preparados para gestionar urgencias asociadas con los trastornos hipertensivos del embarazo. Los desenlaces mejoran con la aplicación de protocolos de emergencia estandarizados, organizados y la participación de equipos multidisciplinarios que garanticen una atención de calidad y un efecto positivo en la morbilidad y mortalidad materna susceptible de prevención.

Abstract OBJECTIVE: To describe the characteristics of the affected population and the delays that contributed to maternal mortality secondary to hypertensive disorders of pregnancy. MATERIALS AND METHODS: Descriptive and retrospective study based on the epidemiologic surveillance of sentinel cases of early maternal deaths of women residing in Antioquia, Colombia, during pregnancy, delivery and the 42 days after delivery occurring in the period 2012-2020. A database was created in Microsoft Access 2007 (Microsoft, Redmond, WA, USA), and data were analyzed in Microsoft Excel and SPSS version 22. RESULTS: There were 266 maternal deaths, of which 38 were secondary to hypertensive disorders of pregnancy. Eclampsia was the cause of 15 deaths; 12 due to HELLP syndrome, 9 due to intracerebral hemorrhage, and 2 due to placental abruption and disseminated intravascular coagulation. In 13 of the 38 cases, there was no adequate magnesium sulfate regimen, 19 did not receive indicated antihypertensive treatment, and 17 did not have adequate antihypertensive control. CONCLUSION: Antenatal care is a critical opportunity for detection, prevention, and risk stratification. All obstetric care centers should be prepared to manage emergencies associated with hypertensive disorders of pregnancy. Outcomes improve with the use of standardized, organized emergency protocols and the participation of multidisciplinary teams that ensure quality care and a positive impact on preventable maternal morbidity and mortality.

Sulfato de magnesio antenatal y eliminación tardía de meconio: Estudio multicéntrico / Antenatal magnesium sulphate and delayed passage of meconium: A multicentre study

Introducción: La relación entre sulfato de magnesio (MgSO4) y el retraso en la evacuación de meconio presenta resultados controvertidos en la literatura. Objetivos: Determinar si existe relación entre la administración de MgSO4 a la madre y la eliminación tardía de meconio (ETM) en el neonato y conocer los niveles de magnesio en sangre en estos, con respecto a la dosis acumulada de MgSO4 administrada a la madre. Población y métodos: Estudio descriptivo-analítico, en pacientes ≤ 32 semanas de edad gestacional, con diseño retrospectivo-prospectivo, llevado a cabo en dos hospitales de tercer nivel asistencial. Se definió la ETM como retraso en la evacuación meconial ≥ 48 horas y/o necesidad de estimulación rectal en ≥ 2 ocasiones para realizar deposición y/o retraso ≥ 48 horas entre la primera y segunda deposición. Resultados: Se reclutaron 283 pacientes (204 retrospectiva y 79 prospectivamente), de los cuales 152 (53,7%) presentó ETM. No se encontró relación entre la administración de MgSO4 a la madre, ni la dosis acumulada de MgSO4 en esta, ni los niveles de magnesio en sangre del neonato con la presencia de ETM. La mayor edad gestacional (OR 0,8, IC 0,69-0,93, p = 0,003) resultó factor protector independiente de la ETM y la necesidad de reanimación avanzada (OR 2,24, IC 1,04-4,86, p = 0,04) factor de riesgo. Conclusiones: Los niveles alcanzados de magnesio en sangre del neonato con las dosis de MgSO4 administradas a las madres, no se relacionan con la ETM. La menor edad gestacional y la necesidad de reanimación avanzada predicen mayor riesgo de ETM. (AU)

Introduction: The published evidence on the association between magnesium sulphate (MgSO4) and delayed passage of meconium (DPM) is contradictory. Objectives: To determine whether there is an association between the administration of MgSO4 to the mother and DPM in the neonate, and to analyse serum magnesium levels in neonates in relation to the cumulative dose of MgSO4 administered to the mother. Population and methods: Retrospective and prospective descriptive and analytical study conducted in patients delivered at or before 32 weeks of gestation in 2 tertiary care hospitals. Delayed passage of meconium was defined as failure to pass meconium within 48 hours of birth and/or need for rectal stimulation on 2 or more occasions to pass stool and/or interval of at least 48 hours between the first and second bowel movements. Results: The study included 283 patients (204 retrospectively and 79 prospectively), of who 152 (53.7%) experienced DPM. Delayed passage of meconium was not associated with antenatal MgSO4 administration, the cumulative maternal MgSO4 dose or neonatal serum magnesium levels. Older gestational age (OR, 0.8; confidence interval [CI], 0.69–0.93; P = .003) was an independent protective factor against DPM, while the need for advanced resuscitation (OR, 2.24; CI 1.04–4.86; P = .04) was a risk factor for DPM. Conclusion: The neonatal serum levels of magnesium reached with the doses of MgSO4 administered to mothers were not associated with DPM. Lower gestational age and the need for advanced resuscitation were predictors associated with an increased risk of DPM. (AU)

Antenatal magnesium sulphate and delayed passage of meconium: A multicentre study.

INTRODUCTION: The published evidence on the association between magnesium sulphate (MgSO4) and delayed passage of meconium (DPM) is contradictory. OBJECTIVES: To determine whether there is an association between the administration of MgSO4 to the mother and DPM in the neonate, and to analyse serum magnesium levels in neonates in relation to the cumulative dose of MgSO4 administered to the mother. POPULATION AND METHODS: Retrospective and prospective descriptive and analytical study conducted in patients delivered at or before 32 weeks of gestation in 2 tertiary care hospitals. Delayed passage of meconium was defined as failure to pass meconium within 48 h of birth and/or need for rectal stimulation on 2 or more occasions to pass stool and/or interval of at least 48 h between the first and second bowel movements. RESULTS: The study included 283 patients (204 retrospectively and 79 prospectively), of who 152 (53.7%) experienced DPM. Delayed passage of meconium was not associated with antenatal MgSO4 administration, the cumulative maternal MgSO4 dose or neonatal serum magnesium levels. Older gestational age (OR, 0.8; confidence interval [CI], 0.69-0.93; P = 0.003) was an independent protective factor against DPM, while the need for advanced resuscitation (OR, 2.24; CI 1.04-4.86; P = 0.04) was a risk factor for DPM. CONCLUSION: The neonatal serum levels of magnesium reached with the doses of MgSO4 administered to mothers were not associated with DPM. Lower gestational age and the need for advanced resuscitation were predictors associated with an increased risk of DPM.

Reporte de seis casos de eclampsia en un hospital rural de la selva de Chiapas / Six Cases of Reports of Eclampsia in a Rural Hospital from the Chiapas Jungle

Resumen La eclampsia es un síndrome relativamente raro e impredecible de la enfermedad hipertensiva inducida por el embarazo, caracterizado por un estado convulsivo tónico-clónico que puede o no cursar con hipertensión previa o daño orgánico. Complica aproximadamente 3 de cada 1,000 embarazos, con alta incidencia en pacientes de zonas rurales y bajo nivel socioeconómico, mujeres con preeclampsia, primigestas adolescentes y multíparas mayores de 35 años de edad. Presentamos el reporte de 6 casos de eclampsia que sucedieron en un hospital rural del estado de Chiapas, ubicado en el corazón de la Selva Lacandona. La mayoría fueron primigestas adolescentes en trabajo de parto, quienes rebasaban las 40 semanas de gestación. Todas fueron manejadas con medidas de soporte y neuroprotección con sulfato de magnesio, 5 de ellas fueron referidas a segundo nivel a la unidad de cuidados intensivos para recibir una atención integral, con un tiempo promedio de estancia de 2 días. Ninguna presentó un nuevo cuadro convulsivo. No se registraron resultados perinatales adversos ni muerte materna. El síndrome preeclampsia-eclampsia es un problema de alto impacto en el embarazo y un reto para los 3 niveles de atención, pero sobre todo para la atención en el medio rural y zonas indígenas de todo México, ya que, debido a costumbres arraigadas, las pacientes omiten el control prenatal, además de habitar en lugares con difícil acceso a hospitales o clínicas.

Abstract Eclampsia is a relatively rare and unpredictable syndrome of pregnancy-induced hypertensive disease, characterized by a tonic-clonic seizure state which may or may not present hypertension or end-organ damage. It complicates approximately 3 out of 1000 pregnancies, with a high incidence in patients of low socioeconomic status and rural areas, women with pre-eclampsia, primiparous teen or multiparous women over 35 years old. We present the report of 6 cases of eclampsia that occurred in a first level rural hospital of attention in the state of Chiapas, located in the heart of the Lacandon Jungle. Most of them occurred in primiparous teen patients during labor, which exceeded 40 weeks of gestation. All were promptly managed with support measures and magnesium sulfate neuroprotection, 5 of them referred to the second level of the intensive care unit for more comprehensive care, the average length of stay was 2 days. No one presented a new seizure. No adverse perinatal outcomes or maternal death were recorded. The pre-eclampsia-eclampsia syndrome is a problem with a high impact on pregnancy and a challenge for all three levels of care, but especially for care in rural areas and indigenous areas throughout Mexico, since, due to entrenched customs, patients omit prenatal control, in addition to living in places with difficult access to hospitals or clinics.

Effects of 4% icodextrine, magnesium sulfate, and 0.9% sodium chloride on postoperative intraabdominal adhesions.

OBJECTIVE: Postoperative intraabdominal adhesions are obvious cause of postoperative morbidity. In this experimental study, our aim is to compare the effects of 4% icodextrin produced for adhesion prevention, magnesium sulfate used as an anticonvulsant in obstetrics and also as a thickening lubricant in the detergent industry, and saline, which we use most frequently in abdominal irrigation, on adhesion formation. MATERIALS AND METHODS: A total of 4 groups were formed, 8 in the control group (K), 8 in the icodextrin group (I), 8 in the magnesium sulfate group (M), and 8 in the saline group (SF). Adhesions were quantitatively evaluated with the classification defined by Nair and microscopic grading defined by Zuhlke. RESULTS: The macroscopic staging degree was statistically significantly lower in Group M, I, and SF compared to Group K. Again, the degree of microscopic staging was significantly lower in Group M and I compared to Group K. CONCLUSIONS: Three different materials were used in our study. It was observed that they significantly reduced adhesions. This study once again demonstrates the limited ability of these materials to prevent adhesion, despite the wide variety of materials used, and the need for careful adherence to tissue-respectful surgical techniques.

OBJETIVO: As aderências intra-abdominais pós-operatórias (PIA) são causa óbvia de morbidade pós-operatória. Neste estudo experimental, nosso objetivo é comparar os efeitos da icodextrina 4% produzida para prevenção de aderências, sulfato de magnésio usado como anticonvulsivante em obstetrícia e também como lubrificante espessante na indústria de detergentes e soro fisiológico, que usamos mais frequentemente em abdominais irrigação, na formação de aderências. MATERIAIS E MÉTODOS: Foram formados 4 grupos, 8 no grupo controle (K), 8 no grupo da icodextrina (I), 8 no grupo sulfato de magnésio (M) e 8 no grupo solução salina (SF). As aderências foram avaliadas quantitativamente com a classificação definida por Nair e graduação microscópica definida por Zuhlke. RESULTADOS: O grau de estadiamento macroscópico foi estatisticamente significativamente menor no Grupo M, I e SF em comparação com o Grupo K. Novamente, o grau de estadiamento microscópico foi significativamente menor nos Grupos M e I em comparação com o Grupo K. CONCLUSÕES: Três materiais diferentes foram usados em nosso estudo. Foi observado que eles reduziram significativamente as aderências. Este estudo demonstra mais uma vez a capacidade limitada desses materiais em prevenir a adesão, apesar da grande variedade de materiais usados, e a necessidade de uma adesão cuidadosa a técnicas cirúrgicas que respeitem o tecido.

A case of aluminum phosphide poisoning managed successfully in Nepal: a case report / Un caso de intoxicación por fosfuro de aluminio manejado con éxito en Nepal: informe de un caso

Aluminum phosphide (ALP) is a highly toxic compound most commonly available as Celphos in Nepal. Suicidal ingestion is common in developing countries like Nepal as it is easily available and has a high mortality rate. Farmers to protect crops from rodents and pests use it. Here we present a case of a 24-year-old female with suicidal ingestion of one and a half-tablet of ALP presented with abdominal pain and vomiting. The patient developed metabolic acidosis, hyperkalemia, acute respiratory distress, and hypotension during the Intensive Care Unit stay. Supportive treatment with gastric lavage (coconut oil), intravenous magnesium sulfate, sodium-bicarbonate infusion, adequate vasopressor and close monitoring of hemodynamic parameters helped in the survival of the patient (AU)

El fosfuro de aluminio (ALP) es un compuesto altamente tóxico más comúnmente disponible como Celphos en Nepal. La ingestión suicida es común en países en desarrollo como Nepal, ya que está fácilmente disponible, teniendo una alta tasa de mortalidad. Los agricultores lo utilizan para proteger los cultivos de roedores y plagas. Aquí presentamos el caso de una mujer de 24 años con ingesta suicida de una tableta y media de ALP que presentó dolor abdominal y vómitos. La paciente desarrolló acidosis metabólica, hiperpotasemia, dificultad respiratoria aguda e hipotensión durante su estancia en la Unidad de Cuidados Intensivos. El tratamiento de soporte con lavado gástrico (aceite de coco), sulfato de magnesio intravenoso, infusión de bicarbonato de sodio, vasopresor adecuado y monitoreo estrecho de los parámetros hemodinámicos ayudaron a la supervivencia del paciente (AU)

Analgesic effect of pregabalin and magnesium sulfate after mastectomy with axillary lymphadenectomy / Efeito analgésico da pregabalina e do sulfato de magnésio no pósoperatório de mastectomia com linfadenectomia axilar

ABSTRACT BACKGROUND AND OBJECTIVES: Mastectomy with lymphadenectomy is a surgery associated with moderate to severe pain in the immediate postoperatory. Several safe adjuvant drugs that provide good analgesia with few adverse effects have been researched. Pregabalin and magnesium sulfate are drugs that promote analgesia with few adverse effects. The objective of the present study was to evaluate the analgesic effect of pregabalin and magnesium sulfate in the postoperatory of mastectomy with axillary lymphadenectomy. METHODS: Double-blinded, randomized study involving 80 patients submitted to mastectomy with axillary lymphadenectomy under general anesthesia. The patients were distributed into 4 groups: Control (CG, did not receive the proposed adjuvant drug); Magnesium+Placebo (MG, received magnesium sulfate during anesthesia); Pregabalin+Magnesium (P+MG, received magnesium added to pregabalin 150 mg before and 12 h after surgery); and Pregabalin+Placebo (PG, received pregabalin). All patients completed the Self-Report Questionnaire 20 (SRQ-20) to screen for possible mental disorders and had their physical status monitored at 1 h, 12 h, and 24 h after surgery, through anamnesis, pain questionnaire, opioid consumption, and presence of complications and/or adverse events such as nausea, vomiting, and sleepiness. Randomization was performed using sealed opaque envelopes without the knowledge of the anesthesiologist (researcher) and the patient. RESULTS: For each group, twenty patients were randomized, which were analyzed at the end of the study. The number of patients presenting absent/mild pain in P+MG was significantly higher than in CG, MG and PG after one hour. After 12 hours, P+MG and PG had more patients with absent/mild pain than CG and MG. At 24 hours postoperatively, all patients in all evaluated groups had no moderate/severe pain. There was no diference in the frequency of patients presenting nausea or vomiting, nor in the scores of the sleep evaluation after surgery in the four groups. CONCLUSION: The combination of magnesium sulfate and pregabalin provided satisfactory analgesia in the first hour after mastectomy with axillary lymphadenectomy. Nevertheless, magnesium sulfate isolated presented no analgesic beneft for the patients, and pregabalin isolated was only slightly effective at the first hour after surgery.

RESUMO JUSTIFICATIVA E OBJETIVOS: Mastectomia com linfadenectomia é uma cirurgia que causa dor moderada ou intensa no pós-operatório imediato. Muitos fármacos adjuvantes, seguros, que promovem boa analgesia e com poucos efeitos adversos têm sido pesquisados. A pregabalina e o sulfato de magnésio são fármacos que promovem analgesia com poucos efeitos adversos. O objetivo deste estudo foi avaliar o efeito analgésico da pregabalina e do sulfato de magnésio no pós-operatório de mastectomia com linfadenectomia axilar. MÉTODOS: Estudo randomizado e duplo-cego envolvendo 80 pacientes submetidas à mastectomia com linfadenectomia axilar sob anestesia geral. As pacientes foram divididas em quatro grupos: Controle (GC, não receberam o fármaco adjuvante proposto); Magnésio+Placebo (GM, receberam sulfato de magnésio durante a anestesia); Pregabalina+Magnésio (GP+M, receberam magnésio adicionado a pregabalina 150 mg antes e 12 h após a cirurgia); e Pregabalina+Placebo (GP, receberam a pregabalina). Todas as pacientes responderam o Self-Report Questionnaire 20 (SRQ-20) para rastrear possível transtorno mental e foram seguidas, monitorando o estado físico 1h, 12h e 24h após a cirurgia, através de anamnese, questionário de dor, consumo de opioides e presença de complicações e/ou eventos adversos como náusea, vômito e sonolência. A randomização foi realizada por meio de envelopes opacos e selados sem o conhecimento do anestesiologista (pesquisador) e do paciente. RESULTADOS: Foram randomizadas 20 pacientes para cada grupo, as quais foram analisadas ao fim do estudo. O número de pacientes apresentando dor ausente/leve no GP+M foi significantemente maior que nos GC, GM e GP após uma hora. Após 12 horas, GP+M e GP apresentaram maior número de pacientes com dor ausente/leve que GC e GM. Em 24 horas do pós-operatório, todos os pacientes de todos os grupos avaliados não apresentaram dor moderada/severa. Não houve diferença na frequência de pacientes apresentando náusea ou vômito, nem nos escores da avaliação do sono após a cirurgia nos quatro grupos. CONCLUSÃO: A associação de sulfato de magnésio e pregabalina causa boa analgesia de mastectomia com linfadenectomia axilar na primeira hora do pós-operatório. No entanto, o uso isolado do sulfato de magnésio não trouxe benefício para analgesia nestas pacientes, assim como a pregabalina sozinha se mostrou pouco efetiva na primeira hora de avaliação.

Prenatal therapy with magnesium sulphate and intestinal obstruction due to meconium in preterm newborns.

INTRODUCTION: Magnesium sulphate (MgSO4) therapy has shown to be useful as a neurological protector in the preterm newborn below 32 weeks of gestation. The most documented adverse effect is cardiorespiratory failure, whereas its relationship with meconium obstruction is controversial. The main objective of this study was to analyse the possible association between prenatal MgSO4 therapy and meconium obstruction. PATIENTS AND METHODS: An analytical retrospective study was conducted on <32 weeks preterm babies admitted to a tertiary-level hospital (January 2016-December 2017). Epidemiological, prenatal and postnatal data on the outcomes were obtained, analysed and compared in both groups (exposed to MgSO4 and not exposed). RESULTS: The study included 201 patients (146 exposed and 55 non-exposed). There were no significant differences in the mean gestational age (28.4 ±â€¯2.2 vs. 28.7 ±â€¯2.8 weeks, respectively), or in the rest of epidemiological and perinatal variables. Prenatal corticosteroid therapy was more frequent in the MgSO4 group (75.9 vs. 53.7%; p = .002), and in the non-exposed group there were more multiple pregnancies (52.7 vs. 36.6%; p = .027), and female gender (56.4 vs. 37%; p = .013). There were no statistically significant differences in the presence of meconium obstruction (75.9% in exposed vs. 67.3% in non-exposed; p = .23), although repeated rectal stimulation was more frequent in the exposed group (43.2 vs. 27.9%; p = .08). Furthermore, there were no significant differences in the main cardiorespiratory variables: 1-min Apgar score (6.2 in MgSO4- exposed vs. 5.6 in non-exposed; p = .75), 5-min Apgar score (7.9 vs. 7.6; p = .31), advanced newborn resuscitation (26 vs. 31.5%; p = .44), maximum FiO2 (45.5 vs. 48; p = .58), and initial inotropic requirements (10.3 vs. 20.8%; p = .55). CONCLUSIONS: This study found no correlations between MgSO4 therapy and meconium obstruction or cardiorespiratory failure.

Terapia prenatal con sulfato de magnesio y obstrucción intestinal por meconio en recién nacidos pretérmino / Prenatal therapy with magnesium sulphate and intestinal obstruction due to meconium in preterm newborns

Introducción: El sulfato de magnesio (SMg) ha demostrado eficacia como neuroprotector en pretérminos < 32 semanas. Su efecto adverso más documentado es la depresión cardiorrespiratoria, siendo dudosa su relación con la obstrucción meconial. El objetivo principal del estudio es analizar la posible asociación entre el SMg antenatal y la obstrucción meconial. Pacientes y métodos: Estudio retrospectivo analítico, de neonatos < 32 semanas de edad gestacional ingresados en un hospital terciario (enero del 2016 a diciembre del 2017). Se recogieron datos epidemiológicos, perinatales y de evolución posnatal, comparando expuestos y no expuestos a SMg. Resultados: Se incluyeron 201 pacientes (146 recibieron SMg y 55 no). No existieron diferencias en la edad gestacional media (28,4 ± 2,2 vs. 28,7 ± 2,8 semanas, respectivamente), ni en el resto de variables epidemiológicas y perinatales, salvo en expuestos, la administración más frecuente de corticoides antenatales (75,9 vs. 53,7%; p = 0,002), y en no expuestos el parto múltiple (52,7 vs. 36,6%; p = 0,027), y el sexo femenino (56,4 vs. 37%; p = 0,013). No hubo diferencias significativas en la obstrucción meconial (75,9% expuestos vs. 67,3% no expuestos; p = 0,23), aunque la estimulación rectal repetida fue más frecuente en el grupo tratado (43,2 vs. 27,9%; (p = 0,08). Tampoco hubo diferencias en las principales variables de depresión cardiorrespiratoria: Apgar al primer minuto 6,2 vs. 5,6 en expuestos y no expuestos, respectivamente (p = 0,75) y a los cinco minutos 7,9 vs. 7,6 (p = 0,31), reanimación avanzada 26 vs. 31,5% (p = 0,44), FiO2 máxima 45,5 vs. 48 (p = 0,58) y necesidad inicial de inotrópicos 10,3 vs. 20,8% (p = 0,55). Conclusiones: El presente estudio no halló asociación entre la administración de SMg y la obstrucción meconial o la depresión cardiorrespiratoria. (AU)

Introduction: Magnesium sulphate (MgSO4) therapy has shown to be useful as a neurological protector in the preterm newborn below 32 weeks of gestation. The most documented adverse effect is cardiorespiratory failure, whereas its relationship with meconium obstruction is controversial. The main objective of this study was to analyse the possible association between prenatal MgSO4 therapy and meconium obstruction. Patients and methods: An analytical retrospective study was conducted on < 32 weeks preterm babies admitted to a tertiary-level hospital (January 2016-December 2017). Epidemiological, prenatal and postnatal data on the outcomes were obtained, analysed and compared in both groups (exposed to MgSO4 and not exposed). Results: The study included 201 patients (146 exposed and 55 non-exposed). There were no significant differences in the mean gestational age (28.4 ± 2.2 vs. 28.7 ± 2.8 weeks, respectively), or in the rest of epidemiological and perinatal variables. Prenatal corticosteroid therapy was more frequent in the MgSO4 group (75.9 vs. 53.7%; p = .002), and in the non-exposed group there were more multiple pregnancies (52.7 vs. 36.6%; p = .027), and female gender (56.4 vs. 37%; p = .013). There were no statistically significant differences in the presence of meconium obstruction (75.9% in exposed vs. 67.3% in non-exposed; p = .23), although repeated rectal stimulation was more frequent in the exposed group (43.2 vs. 27.9%; p = .08). Furthermore, there were no significant differences in the main cardiorespiratory variables: 1-minute Apgar score (6.2 in MgSO4- exposed vs. 5.6 in non-exposed; p = .75), 5-minutes Apgar score (7.9 vs. 7.6; p = .31), advanced newborn resuscitation (26 vs. 31.5%; p = .44), maximum FiO2 (45.5 vs. 48; p = .58), and initial inotropic requirements (10.3 vs. 20.8%; p = .55). Conclusions: This study found no correlations between MgSO4 therapy and meconium obstruction or cardiorespiratory failure. (AU)

Sulfato de magnesio como ahorrador de opioides en cirugía mayor abdominal / Magnesium sulfate as an opioid sparer in major abdominal surgery

Introducción: El efecto del sulfato de magnesio como adyuvante de la analgesia en la práctica de diferentes intervenciones quirúrgicas es un tema en debate y estudio constante con el fin de probar su eficacia y seguridad en la mejora de la evolución posoperatoria de los pacientes. Objetivo: Evaluar la efectividad y seguridad del sulfato de magnesio como ahorrador de opioides en la anestesia general de pacientes intervenidos por cirugía mayor abdominal. Métodos: Estudio cuasiexperimental, prospectivo, longitudinal realizado en 44 pacientes del Hospital Universitario "General Calixto García", desde diciembre de 2019 hasta diciembre de 2020. Se crearon dos grupos, un grupo estudio (sulfato de magnesio) y otro control. Se evaluó la analgesia intraoperatoria y posoperatoria, el consumo intraoperatorio de fentanil, la necesidad de analgesia de rescate y las complicaciones perioperatorias. Resultados: En los pacientes que se les administró el sulfato de magnesio la tensión arterial media, la frecuencia cardiaca y el índice de shock tuvieron una tendencia a mantenerse por debajo de la media global. El índice de perfusión aumentó y se mantuvo con esa tendencia y tuvieron un menor consumo de fentanil. Conclusiones: La administración de sulfato de magnesio como adyuvante de la anestesia general en pacientes intervenidos por cirugía abdominal mayor electiva, resultó efectiva y segura, pues brindó mayor analgesia perioperatoria, estabilidad hemodinámica, menor consumo de opioides intraoperatorio y menor rescate analgésico posoperatorio que cuando no se usó. La incidencia de complicaciones fue baja y sin repercusión clínica(AU)

Introduction: The effect of magnesium sulfate as an adjunct to analgesia during different surgical interventions is a subject under constant debate and study, with respect to showing its efficacy and safety in improving the postoperative evolution of patients. Objective: To assess the effectiveness and safety of magnesium sulfate as an opioid sparer in general anesthesia with patients undergoing major abdominal surgery. Methods: Quasiexperimental, prospective and longitudinal study carried out, from December 2019 to December 2020, with 44 patients from General Calixto García University Hospital. Two groups were created: a study group (magnesium sulfate) and a control group. Intraoperative and postoperative analgesia, intraoperative fentanyl consumption, requirement of salvage analgesia, as well as perioperative complications were evaluated. Results: In the patients who were administered magnesium sulfate, mean arterial pressure, heart rate and shock index tended to remain below the global mean. The perfusion index increased and maintained this trend, while they had a lower consumption of fentanyl. Conclusions: The administration of magnesium sulfate as an adjunct to general anesthesia in patients undergoing major elective abdominal surgery was effective and safe, as it provided greater perioperative analgesia, hemodynamic stability, less intraoperative opioid consumption and less postoperative analgesic rescue than in the control group. The incidence of complications was low and without clinical repercussions(AU)

Ventajas del sulfato de magnesio en anestesiología / Advantages of magnesium sulfate in anesthesiology

Objetivos: explicar la utilidad del sulfato de magnesio en el área de anestesiología con la información disponible de libre acceso. Material y métodos: para alcanzar el objetivo se realizó una revisión bibliográfica de ensayos clínicos, meta análisis publicados en importantes plataformas de datos de ciencia médicas. Con palabras de búsqueda como: anestesiología y sulfato de magnesio, analgesia, relajantes musculares, escalofríos, Ginecología-Eclampsia. Resultados: se obtuvo información variada en el ámbito de anestesiología, seleccionando aquellos que hacen referencia en al ámbito de anestesiología, realizando la combinación de palabras, se obtuvo en google académico de alrededor de 114 artículos relacionados, de los cuales se eligió aquellos ensayos clínicos y meta análisis. Conclusiones: se concluyó que el sulfato de magnesio ayuda en disminución de la dosis de los anestésicos, sin embargo, no es concluyente que como adyuvante ayude en la analgesia. Se observó que prolonga la acción de los relajantes musculares. Se sugiere permanecer con los estudios para revelar la dosis, inicio de administración, calidad para la inclusión en estudios de meta análisis.

Objectives: Explain the usefulness of magnesium sulphate in the area of anesthesiology with the freely available information. Material and methods: To achieve the objective, a bibliographic review of clinical trials was carried out, meta-analyzes published in important medical science data platforms. With search words like: anesthesiology and magnesium sulfate, analgesia, muscle relaxants, chills, Gynecology-Eclampsia. Results: A variety of information was obtained in the field of anesthesiology, selecting those that refer to the field of anesthesiology, it was obtained in academic google by combining the words of around 114 related articles, of which those clinical trials and also meta-analysis. Conclusions: It is concluded that magnesium sulfate helps in reducing the dose of anesthetics, however it is not conclusive that as an adjuvant it helps in analgesia. It was observed to prolong the action of muscle relaxants. It is suggested to stay with the studies to reveal the dose, initiation of administration, quality for inclusion in meta-analysis studies.

Morbimortalidad asociada al parto prematuro y su relación con el uso de corticoides y sulfato de magnesio / Morbidity and mortality associated with preterm birth and its relationship with the use of corticosteroids and magnesium sulphate

Introducción: El parto prematuro está asociado a múltiples complicaciones, con un aumento de la morbimortalidad perinatal. Sin embargo, muchos estudios apoyan el uso de corticoides y sulfato de magnesio para mejorar los resultados en estos recién nacidos prematuros. El objetivo de nuestro estudio es describir la incidencia de morbimortalidad en recién nacidos prematuros de nuestro entorno y cómo el uso tanto de corticoides como de sulfato de magnesio ha mejorado el pronóstico a corto plazo de estos recién nacidos. Material y métodos: Estudio retrospectivo observacional de 564 recién nacidos prematuros nacidos entre 2018-2019 en el área hospitalaria del Hospital Juan Ramón Jiménez. El tratamiento con corticoides y sulfato de magnesio se realizó según los protocolos actuales de la Sociedad Española de Ginecología y Obstetricia. Resultados: La incidencia de prematuridad fue del 7,9% en nuestro entorno. La gestación gemelar junto con la enfermedad hipertensiva del embarazo fueron las afecciones obstétricas más frecuentes. La cesárea fue la vía de finalización más común en todos los grupos de prematuridad, excepto en la tardía. El síndrome de distrés respiratorio fue la enfermedad más frecuente (más del 33%) en todos los grupos. La tasa de mortalidad neonatal total fue del 1,8%. En cuanto a los corticoides, el principal resultado de nuestra muestra fue una disminución en la morbimortalidad neonatal, estadísticamente significativa en el síndrome de distrés respiratorio y la retinopatía del prematuro. En cuanto al sulfato de magnesio, el principal resultado fue la disminución de la hemorragia intraventricular, la leucomalacia periventricular y la displasia broncopulmonar. Respecto a la mortalidad neonatal, no hubo diferencias significativas. Conclusiones: La morbimortalidad registrada en nuestra muestra fue similar a la descrita en la bibliografía. El tratamiento con corticoides para la maduración pulmonar redujo la morbimortalidad neonatal en general...(AU)

Introduction: Preterm labour is associated with multiple complications, with an increased risk of perinatal morbidity and mortality. Nevertheless, many studies support the use of corticosteroids and magnesium sulphate to improve outcomes in preterm birth. The objective of this study is to describe the morbidity and mortality incidence in preterm birth in a Spanish hospital and how the use of corticosteroids and magnesium sulphate has improved the short-term prognosis in these newborns. Material and methods: Observational retrospective study of 564 preterm births between the years 2018 to 2019, in the hospital area Juan Ramón Jiménez (Huelva). The treatment with corticosteroids and magnesium sulphate was performed based on current protocols of the Spanish Society of Gynaecology and Obstetrics. Results: The incidence of prematurity in this study was 7.9%. Twin pregnancies and hypertensive pregnancy disease were the most common obstetric disorders. The most common type of delivery was caesarean section in all prematurity groups, except late prematurity. Respiratory distress syndrome was the most frequent pathology (more than 33%) in all groups. Overall neonatal mortality was 1.8‰. As regards the use of corticosteroids, the main outcome was a decrease in neonatal morbidity and mortality, which was statistically significant in respiratory distress syndrome and preterm retinopathy. The use of magnesium sulphate caused a decrease in the incidence of intraventricular haemorrhage, periventricular leukomalacia, and bronchopulmonary dysplasia. There were no significant differences in neonatal mortality. Conclusions: Morbidity and mortality registered in this study were similar to that described in the literature. Although the use of corticosteroids reduced neonatal morbidity and mortality in this study...(AU)

Uso de sulfato de magnesio relacionado con la reanimación neonatal en prematuros / Use of magnesium sulfate in the neonatal reanimation of prematures / Uso de sulfato de magnésio relacionado à ressuscitação neonatal em prematuros

RESUMEN Introducción: La neuroprotección farmacológica se utiliza en el período antenatal para ayudar a disminuir el riesgo de parálisis cerebral o disfunciones motoras en el recién nacido (RN). El sulfato de magnesio (MgSO4) es de gran utilidad por los beneficios que proporciona como tocolítico, neuroprotector fetal en prematuros menores a 32 semanas y en el manejo de la preeclampsia. Sin embargo, durante su uso se observaron efectos adversos a dosis dependientes tanto para la madre como para el RN, lo que genera gran importancia para el trabajo del profesional de obstetricia y enfermería. Objetivo: Determinar la frecuencia de reanimación neonatal en prematuros menores de 32 semanas según el uso de neuroprotección con MgSO4. Métodos: Estudio retrospectivo, observacional, realizado en un hospital de Santiago de Chile. Se realizó un muestreo aleatorio simple. Se incluyeron prematuros menores a 32 semanas de edad gestacional con o sin tratamiento de MgSO4 que hayan requerido o no reanimación neonatal. La información fue recogida a partir de fichas clínicas con un instrumento propio. Análisis de los datos por determinación de frecuencias absolutas y relativas de las variables y su comparación directa. Resultados: Del total de los RN que recibieron MgSO4, 61.7 % requirió reanimación neonatal al nacer, de los que no recibieron este neuroprotector, el 52.8 % necesitó reanimación neonatal. Conclusiones: La mayor frecuencia de reanimación neonatal está asociada al uso de la neuroprotección con MgSO4 y ocurre más probablemente en recién nacidos de edad gestacional menor que 32 semanas. Los resultados contribuyen a la toma de decisiones basadas en pruebas.

ABSTRACT Introduction: Diverse drug-related neuroprotections are used during the prenatal period to help reduce the risk of cerebral palsy or motor dysfunctions in the newborn. Magnesium sulfate (MgSO4) is useful as a fetal neuroprotector in prematures with less than 32 weeks, as well as in the management of preeclampsia. Nevertheless, some dose-dependent adverse effects both on the mother and the newborn have been reported. This situation is necessarily of concern to the nursing and obstetrics professional. Objective: To determine the frequency of neonatal reanimation en prematures with less than 32 weeks with MgSO4 neuroprotection. Methods: This is a retrospective and observational study conducted in a hospital in Santiago, Chile. Simple random sampling was used. Prematures with less than 32 weeks of gestational age, with or without MgSO4 treatment and who had or had not required neonatal reanimation, were included in the study. Data were collected from clinical records. Absolute and relative frequencies and their direct comparisons were calculated. Results: From the total of newborns who received MgSO4, 61.7% required neonatal reanimation, while from those who did not receive MgSO4, 52.8% required neonatal reanimation. Conclusions: The higher frequency of neonatal reanimation is associated with the received MgSO4 as a neuroprotection with and occurs more likely in neonates with a gestational age less than 32 weeks. The results contribute to evidence-based decision making.

RESUMO Introdução: A neuroproteção farmacológica é utilizada no período pré-natal para ajudar a reduzir o risco de paralisia cerebral ou disfunções motoras no recém-nascido (RN). O sulfato de magnésio (MgSO4) é muito útil devido aos benefícios que proporciona como tocolítico, neuroprotetor fetal em prematuros com menos de 32 semanas e no tratamento da pré-eclâmpsia. Porém, durante seu uso, foram registrados efeitos adversos em doses dependentes tanto para a mãe quanto para o recém-nascido, o que gera grande importância para o trabalho do profissional obstétrico e de enfermagem. Objetivo: Determinar a frequência de reanimação neonatal em prematuros com menos de 32 semanas de acordo com o uso de neuroproteção com MgSO4. Métodos: Estudo retrospectivo e observacional realizado em um hospital de Santiago de Chile. Foi realizada uma amostragem aleatória simples. Foram incluídos bebês prematuros com menos de 32 semanas de idade gestacional com ou sem tratamento com MgSO4 que exigia ou não a reanimação neonatal. Coletou-se informação de prontuários clínicos com um instrumento proprietário. Análise dos dados através da determinação das frequências absolutas e relativas das variáveis e sua comparação direta. Resultados: Do total dos RN que receberam MgSO4, 61,7% necessitaram de reanimação neonatal ao nascimento, dos que não receberam esse neuroprotetor, 52,8% necessitaram de reanimação neonatal. Conclusões: A frequência de reanimação neonatal foi maior em recém-nascidos com menos de 32 semanas de idade gestacional que receberam neuroproteção com MgSO4, situação semelhante em cada estrato de idade gestacional.

Prematuro con perforación intestinal espontánea de presentación muy precoz / Preterm neonate with spontaneous intestinal perforation of very early presentation

Resumen Introducción: La perforación intestinal espontánea es una condición que afecta principalmente a neonatos pretérmino. Caso clínico: Se presenta el caso de un neonato pretérmino de 26 semanas de gestación con neumoperitoneo en las primeras 24 horas de vida. Por lo precoz del cuadro y los hallazgos radiológicos, la primera hipótesis diagnóstica fue una perforación gástrica. Sin embargo, en la laparotomía se encontró una perforación ileal única, sin hallazgos de enterocolitis. Conclusiones: La perforación intestinal espontánea se ha asociado con intervenciones médicas, como el uso concomitante de esteroides e indometacina. Otras intervenciones, como el uso de magnesio prenatal y la colocación de surfactante pulmonar de forma mínimamente invasiva, se han propuesto como factores de riesgo para su desarrollo. En la actualidad, deben evaluarse la perforación intestinal espontánea y sus asociaciones. Las presentes y futuras investigaciones podrían contribuir a aclarar el papel de las intervenciones mencionadas en la revisión preliminar de la literatura.

Abstract Background: Spontaneous intestinal perforation is a condition that mainly affects preterm infants. Case report: The case of a preterm infant of 26 weeks of gestation with pneumoperitoneum in the first 24 hours of life is described. Due to the early symptoms and radiological findings, the first diagnostic hypothesis was gastric perforation. However, at laparotomy, a unique ileal perforation was found, without findings of enterocolitis. Conclusions: Spontaneous intestinal perforation is a complication associated with medical interventions such as the concomitant use of steroids and indomethacin. Recently, other interventions, such as the use of prenatal magnesium and treatment with exogenous pulmonary surfactants in a minimally invasive way have been proposed as risk factors for its development. At present, clinicians should evaluate spontaneous intestinal perforation and its associations, and ongoing and future research may clarify the role of the interventions mentioned in the review of preliminary literature.

[Preterm neonate with spontaneous intestinal perforation of very early presentation]. / Prematuro con perforación intestinal espontánea de presentación muy precoz.

Introducción: La perforación intestinal espontánea es una condición que afecta principalmente a neonatos pretérmino. Caso clínico: Se presenta el caso de un neonato pretérmino de 26 semanas de gestación con neumoperitoneo en las primeras 24 horas de vida. Por lo precoz del cuadro y los hallazgos radiológicos, la primera hipótesis diagnóstica fue una perforación gástrica. Sin embargo, en la laparotomía se encontró una perforación ileal única, sin hallazgos de enterocolitis. Conclusiones: La perforación intestinal espontánea se ha asociado con intervenciones médicas, como el uso concomitante de esteroides e indometacina. Otras intervenciones, como el uso de magnesio prenatal y la colocación de surfactante pulmonar de forma mínimamente invasiva, se han propuesto como factores de riesgo para su desarrollo. En la actualidad, deben evaluarse la perforación intestinal espontánea y sus asociaciones. Las presentes y futuras investigaciones podrían contribuir a aclarar el papel de las intervenciones mencionadas en la revisión preliminar de la literatura.

Efectividad de un tratamiento acortado con sulfato de magnesio para prevención de eclampsia durante el puerperio / Effectiveness of a shortened treatment with magnesium sulfate for prevention of eclampsia during puerperium

Resumen OBJETIVO: Determinar si la administración de un tratamiento acortado, menor de 8 h, con sulfato de magnesio durante el puerperio es efectivo para prevenir eclampsia y conseguir algunas otras ventajas. MATERIAL Y MÉTODOS: Estudio de serie de casos, retrospectivo, transversal y comparativo efectuado en el Hospital Regional Materno Infantil de Nuevo León, México, de febrero de 2019 a enero de 2020. Criterios de inclusión: pacientes con embarazo único complicado con preeclampsia con datos de severidad o hipertensión crónica con preeclampsia severa sobreagregada a quienes se administró sulfato de magnesio como profilaxis para eclampsia antes del nacimiento y que, posteriormente, continuaron su administración en el puerperio. Las pacientes se dividieron en dos grupos según las horas que recibieron sulfato de magnesio durante el puerperio: grupo A: tratamiento acortado menor de 8 h y grupo B: con esquema de más de 8 h. Para comparar proporciones se utilizó la prueba de χ2. Se consideró con significación estadística el valor de p ≤ 0.05. RESULTADOS: Se analizaron 379 participantes: 76 en el grupo A y 303 en el B. No se registró ningún caso de eclampsia en ambos grupos. Las horas para iniciar la lactancia, deambulación, permanencia de la sonda Foley y en cuidados intensivos fueron significativamente menores en el grupo de tratamiento acortado (14.1 vs 26.06; p =.000), (15.1 vs 26.24; p = .000), (14.5 vs 25.3; p = 000), (13.8 vs 23.1; p = .000), respectivamente. No se observó diferencia en las complicaciones neonatales. CONCLUSIÓN: La administración de un tratamiento acortado de sulfato de magnesio durante el puerperio es igual de efectivo que un tratamiento mayor de 8 h para prevención de eclampsia.

Abstract OBJECTIVE: To determine whether the administration of a shortened treatment of less than 8 h with magnesium sulfate during the puerperium is effective to prevent eclampsia and to achieve some other advantages. MATERIAL AND METHODS: A retrospective, cross-sectional, comparative, retrospective, case series study performed at the Hospital Regional Materno Infantil of Nuevo León, Mexico, from February 2019 to January 2020. Inclusion criteria: patients with singleton pregnancy complicated with preeclampsia with data of severity or chronic hypertension with severe over-added preeclampsia who were administered magnesium sulfate as prophylaxis for eclampsia before birth and subsequently continued its administration in the puerperium. The patients were divided into two groups according to the hours that they received magnesium sulfate during the puerperium: group A: shortened treatment of less than 8 h and group B: with a schedule of more than 8 h. The proportions were compared by using the test for the proportion of patients who received magnesium sulfate during the puerperium. To compare proportions, we used the . A value of p ≤ 0.05 was considered statistically significant. RESULTS: 379 participants were analyzed: 76 in group A and 303 in group B. No cases of eclampsia were recorded in both groups. Hours to initiate breastfeeding, ambulation, Foley tube stay and intensive care were significantly lower in the shortened treatment group (14.1 vs 26.06; p = .000), (15.1 vs 26.24; p = .000), (14.5 vs 25.3; p = 000), (13.8 vs 23.1; p = .000), respectively. No difference in neonatal complications was observed. CONCLUSION: Administration of a shortened course of magnesium sulfate during the puerperium is as effective as a longer course of 8 h for prevention of eclampsia.

[Prenatal therapy with magnesium sulphate and intestinal obstruction due to meconium in preterm newborns]. / Terapia prenatal con sulfato de magnesio y obstrucción intestinal por meconio en recién nacidos pretérmino.

INTRODUCTION: Magnesium sulphate (MgSO4) therapy has shown to be useful as a neurological protector in the preterm newborn below 32 weeks of gestation. The most documented adverse effect is cardiorespiratory failure, whereas its relationship with meconium obstruction is controversial. The main objective of this study was to analyse the possible association between prenatal MgSO4 therapy and meconium obstruction. PATIENTS AND METHODS: An analytical retrospective study was conducted on < 32 weeks preterm babies admitted to a tertiary-level hospital (January 2016-December 2017). Epidemiological, prenatal and postnatal data on the outcomes were obtained, analysed and compared in both groups (exposed to MgSO4 and not exposed). RESULTS: The study included 201 patients (146 exposed and 55 non-exposed). There were no significant differences in the mean gestational age (28.4 ± 2.2 vs. 28.7 ± 2.8 weeks, respectively), or in the rest of epidemiological and perinatal variables. Prenatal corticosteroid therapy was more frequent in the MgSO4 group (75.9 vs. 53.7%; p = .002), and in the non-exposed group there were more multiple pregnancies (52.7 vs. 36.6%; p = .027), and female gender (56.4 vs. 37%; p = .013). There were no statistically significant differences in the presence of meconium obstruction (75.9% in exposed vs. 67.3% in non-exposed; p = .23), although repeated rectal stimulation was more frequent in the exposed group (43.2 vs. 27.9%; p = .08). Furthermore, there were no significant differences in the main cardiorespiratory variables: 1-minute Apgar score (6.2 in MgSO4- exposed vs. 5.6 in non-exposed; p = .75), 5-minutes Apgar score (7.9 vs. 7.6; p = .31), advanced newborn resuscitation (26 vs. 31.5%; p = .44), maximum FiO2 (45.5 vs. 48; p = .58), and initial inotropic requirements (10.3 vs. 20.8%; p = .55). CONCLUSIONS: This study found no correlations between MgSO4 therapy and meconium obstruction or cardiorespiratory failure.

El paciente con estado migrañoso en urgencias / Patient with status migrainosus in emergency department

RESUMEN Se presentan dos casos de la práctica diaria, de pacientes con migraña con y sin aura que evolucionan a estado migrañoso (SM) y requieren atención hospitalaria. El manejo hospitalario es necesario luego de que se agotaran todas las medidas de manejo ambulatorio indicadas. Se describen los criterios diagnósticos del SM actuales por la ICDH-3, su fisiopatología y la reciente propuesta del SM episódico. Se ofrecen algunas sugerencias del manejo actual de acuerdo con la evidencia disponible que pueden ser de utilidad en la práctica diaria.

SUMMARY We describe two cases with migraine with and without aura who evolves to Migrainous State (MS) requiring hospital care. Admision for management is necessary after all outpatient management measures were exhausted. The current criteria for the diagnosis of MS by the ICDH -3, its pathophysiology and the recent proposal of episodic MS were described. We propose some suggestions of current management according to the available evidence that may be useful for daily practice.